AU Patent

AU2014200550A1 — Inhibitors of hepatitis C virus replication

Assigned to Merck Sharp and Dohme LLC · Expires 2014-02-20 · 12y expired

What this patent protects

INHIBITORS OF HEPATITIS C VIRUS REPLICATION Abstract ( (R The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for tre…

USPTO Abstract

INHIBITORS OF HEPATITIS C VIRUS REPLICATION Abstract ( (R The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014200550A1
Jurisdiction
AU
Classification
—
Expires
2014-02-20
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.